GLP-1 agonist treatment: Implications for diabetic retinopathy screening

Abstract Rapid improvement in glycaemic control induced by GLP-1 agonist therapy could be yet another illustration of transient or permanent progression of diabetic retinopathy, similar to documented examples such as pregnancy and continuous subcutaneous insulin infusion. Specific guidelines would b...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes research and clinical practice 2011-12, Vol.94 (3), p.e68-e71
Main Authors: Varadhan, Lakshminarayanan, Humphreys, Tracy, Hariman, Christian, Walker, Adrian B, Varughese, George I
Format: Article
Language:English
Subjects:
Adult
Aged
Diabetes Complications - diagnosis
Diabetes Complications - drug therapy
Diabetes Mellitus, Type 2 - drug therapy
Diabetic Retinopathy - diagnosis
Diabetic Retinopathy - etiology
Endocrinology & Metabolism
Female
GLP-1 agonist
Glucagon-Like Peptide 1 - agonists
Glucagon-Like Peptide 1 - therapeutic use
Humans
Insulin Infusion Systems
Male
Mass Screening
Middle Aged
Pregnancy
Pregnancy in Diabetics - diagnosis
Pregnancy in Diabetics - etiology
Prognosis
Retinopathy
Retrospective Studies
Screening
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Rapid improvement in glycaemic control induced by GLP-1 agonist therapy could be yet another illustration of transient or permanent progression of diabetic retinopathy, similar to documented examples such as pregnancy and continuous subcutaneous insulin infusion. Specific guidelines would be needed to monitor this paradoxical phenomenon during treatment with GLP-1 agonists.
ISSN:0168-8227
1872-8227
DOI:10.1016/j.diabres.2011.08.017